...
首页> 外文期刊>Modern rheumatology >Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG
【24h】

Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG

机译:在难治性糖皮质激素,环磷酰胺和IVIG的病例中,成功的联合利妥昔单抗成功治疗嗜酸性肉芽肿性多血管炎(EGPA;以前为Churg-Strauss综合征)

获取原文
获取原文并翻译 | 示例

摘要

A 44-year old woman with eosinophilic granulomatosis with polyangiitis (EGPA) developed sequential paralysis of different cranial nerves despite treatments including methylpredonisolone pulse therapy, intravenous immunoglobulins (IVIG), and cyclophosphamide. Infusions of rituximab ameliorated her neurological symptoms and serological inflammatory findings. Rituximab, a specific B cell-targeting therapy, might off er an alternative for refractory EGPA with possible advantages of cost and ease of use compared to IVIG, which also targets (at least in part) B lymphocytes and immunoglobulin production.
机译:尽管有包括甲基泼尼松龙脉冲治疗,静脉内免疫球蛋白(IVIG)和环磷酰胺在内的治疗,一名44岁的嗜酸性肉芽肿伴多血管炎(EGPA)的妇女发生了不同颅神经的顺序性麻痹。输注利妥昔单抗改善了她的神经系统症状和血清学炎症反应。与IVIG相比,利妥昔单抗是一种针对B细胞的特异性治疗方法,可能提供难治性EGPA的替代方法,具有成本和易用性优势,IVIG也至少(部分)针对B淋巴细胞和免疫球蛋白的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号